期刊文献+

Dukes B期结直肠癌根治术后复发转移分析 被引量:5

Analysis of recurrence of Dukes B colorectal cancer following radical surgery
在线阅读 下载PDF
导出
摘要 目的探讨Dukes B期结直肠癌根治术后复发转移相关的临床病理因素。方法应用单因素分析法,回顾性分析1990-1999年265例Dukes B期结直肠癌根治术病例的临床病理因素。结果单因素分析显示,Dukes B期大肠癌的预后与肿瘤部位有关,直肠癌术后更易发生复发转移,特别是局部复发。而性别、年龄、病程、大体类型、肿瘤大小、组织学类型、分化程度、肠壁浸润深度与术后复发转移无关。结论Dukes B期的直肠癌患者术后局部复发的风险较大。 Objective To investigate the clinicopathologic factors leading to recurrence of Dukes B (T3-4 N0M0 ) colorectal cancer following radical surgery. Methods Clinicalpathological factors leading to recurrence in 265 cases with colorectal cancer at Dukes B treated with radical surgery from 1990 to 1999 were retrospectively analyzed by using univariate method. There were 220 cases without recurrence and 45 with recurrence. Results Univariate analysis showed that prognosis of colorectal cancer at Dukes B was significantly associated with site of tumor. Tumor recurrence and metastasis, especially local metastasis, could easily occur after surgery for rectal cancer. Yet, age, gender, symptom duration, gross findings, histological differentiation, tumor size and depth of bowel wall invasion were not associated with tumor recurrence. Conclusion Cases with rectal cancer at stage of Dukes B have additional risks for postoperative local recurrence.
出处 《消化外科》 CSCD 2006年第6期424-427,共4页 Journal of Digestive Surgery
基金 广西科学基金(桂科青0542051)
关键词 结直肠癌 根治术 复发 转移 Colorectal cancer Radical surgery Recurrence Metastasis
  • 相关文献

参考文献9

  • 1Burdy G,Panis Y,Alves A,et al.Identifying patients with T3-T4 node-negative colon cancer at high risk of recurrence[J].Dis Colon Rectum,2001,44(11):1682-1688.
  • 2Killingback M,Barron P,Dent O F.Local recurrence after curative resection of cancer of the rectum without total mesorectal excision[J].Dis Colon Rectum,2001,44(4):473-483.
  • 3Park Y J,Park K J,Park J G,et al.Prognosis factor in 2230 Korean colorectal cancer patients:analysis of consecutively operated cases[J].World J Surg,1999,23(7):721-726.
  • 4Roncucci L,Fante R,Losi L,et al.Survival for colon and rectal cancer in a population based cancer registry[J].Eur J Cancer,1996,32A(2):295-302.
  • 5Kraemer M,Wiratkapun S,Seow-Choen F,et al.Stratifying risk factors for follow-up:a comparison of recurrent and nonrecurrent colorectal cancer[J].Dis Colon Rectum,2001,44(6):815-821.
  • 6汪建平,杨祖立,王磊,董文广,黄奕华,覃建章,詹文华.结直肠癌临床病理特征与预后的多因素回归分析[J].中华肿瘤杂志,2003,25(1):59-61. 被引量:122
  • 7Mulcahy H E,Toner M,Patchett S E,et al.Identifying stage B colorectal cancer patients at high risk of tumor recurrence and death[J].Dis Colon Rectum,1997,40(3):326-331.
  • 8万德森,丁培荣,伍小军,李力人,潘志忠,周志伟,卢震海,陈功.直肠癌根治术的远期疗效分析[J].中华胃肠外科杂志,2005,8(4):301-303. 被引量:18
  • 9Walker J,Quirke P.Prognosis and response to therapy in colorectal cancer[J].Eur J Cancer,2002,38(7):880-886.

二级参考文献19

  • 1梁寒,郝希山,王仆,王晓娜,李景武,王家仓,王殿昌.影响直肠癌患者术后生存的多因素Cox回归分析[J].中华肿瘤杂志,2004,26(11):688-691. 被引量:18
  • 2Shephers NA, Saraga EP, Love SB, et al. Prognostic factors in colonic cancer. Histopathology, 1989,14:613-620.
  • 3Ponz de Leon M, Sant M, Micheli A, et al. Clinical and pathologic prognostic indicators in colorectal cancer: a population-based study.Cancer, 1992,69:625-635.
  • 4Deans GT, Patterson CC, Parks TG, et al. Colorectal carcinoma:importance of clinic and pathological factors in survival. Ann R Coil Surg Engl, 1994,76:59-64.
  • 5Park YJ, Park K.l, Park JG, et al. Prognostic factors in 2230 Korean colorectal cancer patients: analysis of consecutively operated cases.World J Surg, 1999,23:721-726.
  • 6Newland RC, Dent OF, Kyttle MN, et al. Pathological determinants of survival associated with colorectal cancer with lymph node metastasis: a multivariate analysis of 579 patients. Cancer, 1994,73:2076-2082.
  • 7Roncucci L, Fante R, Losi L, et al. Survival for colon and rectal cancer in a population based cancer. Br J Surg, 1995,32A:295.
  • 8Laurent-Puig P, Olschwang S, Delattre O, et al. Survival and acquired genetic alteration in colorectal cancer Gastroenterology, 1992,102:1136-1141.
  • 9Ratto C, Soft L, Ippoliti M, et al. Prognostic factors in colorectal cancer literature review for clinical application. Dis Colon Rectum, 1998,41:1033-1049.
  • 10Crucitti F, Sofo L, Doglietto GB, et al. Prognostic factors in colorectal cancer: current status and new trends. J Surg Oncol Suppl, 1991,2:76-82.

共引文献138

同被引文献41

  • 1Therasse P, Arbuck SG, Eisenhauer EA. New guidelines to evaluate the response to treatment in solid tumors [ J]. Na Cancer Inst, 2000,92(3) :205 -216.
  • 2Colevas AD, Setser A. The NCI common terminology criteria for advase events (CTCAE) v3.0 is the new satandard for oneology clinical trials[J].Clin Oncol,2004,22 (14S) : 176 - 181.
  • 3Goldberg RM, Sargent DJ. A randomized controlled trial of fluomuracil plus leucovorin,irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer[ J]. J Clin Oncol,2004,22 ( 1 ) : 23 - 30.
  • 4Feliu J, Salud A, Escudero P, et al. XELOX (eapeeitabine plus oxaliplatin) as first - line treatment for elderly patients over 70 years of age with advanced colorectal cancer[ J]. Br J Cancer,2006,94 (7) :969 -975.
  • 5Comella P, Natale D, Farris A, et al. capecitabine plus oxaliplat in for the first - line treatment of elderly patients with metastatic colorectal earcinoma:final results of the Southern Italy Cooperative Oncology Group Trial 0108[ J]. Cancer,2005,104(2) :282 -289.
  • 6Cassidy J, Tabemero J. XELOX ( capecitabine plus oxaliplatin) : active first - line therapy for patients with metastatic colorectal cancer[J]. J Clin Oncol,2004,22( 11 ) :2084 - 2091.
  • 7Scheithauer W, Komek GV, Raderer M, et al. Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first - line treatment in advanced colorectal cancer[J]. J Clin Oncol,2003,21 (7) : 1307 - 1312.
  • 8ROUGIER PH, PAILLOT B,LA PLANCHE A,et al. 5-fluorouracil continous intravenous infusion compared with bious administration stration: final results of a randomized trail inmetastatie colorectalcancer[J]. Eur J Cancer, 1997,33(11):1789 - 1793.
  • 9GIACCHETTI S, PERPOINT B, ZIGANI R ,et al. Phase III multicenter randomized trail of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer [ J ]. J Clin Oncol, 2000,18 ( 1 ) : 136 - 147.
  • 10DE GRAMONT A, FIGER A, SEYMOUR M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [ J ]. J Clin Oncol, 2000,18 (16) : 2938 - 2947.

引证文献5

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部